Danielle Hicks is Chief Patient Officer at GO2 Foundation for Lung Cancer and has been working in lung cancer non-profit for the past 13 years. She is responsible for all aspects of patient programming, services, engagement and empowerment along with strategic insight and planning around lung cancer awareness and education. Through personal history with lung cancer, Bonnie Addario is her mother, she has had hands on experience as a caregiver as it relates to lung cancer the disease, treatments, the emotional and physical experience along with experience through survivorship. She has developed multiple patient education programs and educational publications that have reach in 143 countries around the world. In her role she directly touches patients, caregivers, physicians, nurses and industry professionals. She attends scientific meetings specific to lung cancer, has sat on multiple advisory boards, and has experience with speaking engagements across the lung cancer community.

Lesli Kiedrowski is the Director of Medical Affairs in Oncology at Guardant Health. She and her team collaborate with clinician and biopharma partners to advance the fields of liquid biopsy and precision oncology through research projects ranging from clinical utility and implementation of genomic profiling to exploratory biomarker assessment. Prior to joining the team at Guardant Health six years ago, Lesli worked in clinical care as a genetic counselor, primarily seeing patients for hereditary cancer risk assessment and management.

Hillary Stires serves as a Science Policy Analyst at Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, DC that drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients. For more than two decades, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible. At Friends, Hillary supports the development and implementation of the organization’s research and policy agenda. She uses her scientific and advocacy background to develop evidence based policies. Hillary collaborates with diverse teams to identify challenges in cancer research and create solutions that improve and accelerate cancer care for patients. She runs Friends’ ctDNA for Monitoring Treatment Response (ctMoniTR) Project, a first of its kind partnership working to answer the important question: Do changes in ctDNA reflect response to treatment? Hillary received her PhD in endocrinology and animal biosciences from Rutgers University and completed a postdoctoral fellowship in tumor biology at Georgetown University’s Lombardi Comprehensive Cancer Center. Her research focused on tumor development and drug resistance in hormone dependent breast cancer.

Blueprint Medicines is a global precision therapy company that aims to invent life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. (US-BP-MED-NP-22031)

Will be added soon